Investors should skip buying Merck shares because of valuation and political risk, BMO Capital said. » Read More
U.S. stocks closed lower Monday, despite gains in oil, as the S&P 500 and Nasdaq composite ended February with losses.
Using Kensho, a quant tool used by hedge funds, CNBC Pro searched for the stocks that showed the least correlation with the price of oil.
U.S. equities closed sharply higher on Friday as European and American bank stocks — as well as oil prices — bounced sharply.
CNBC contributor Michael Santoli looks at companies with dividend yield that is higher than their corporate debt.
Stocks close sharply lower amid a massive drop in technology stocks and concerns the Fed may raise rates this year.
U.S. stocks closed mostly higher on Wednesday, with the Dow and S&P completing a massive comeback spurred by a surge in oil.
U.S. stock index futures pointed to a mostly higher open on Wednesday after a better-than-expected ADP jobs report.
Some of the names on the move ahead of the open.
Merck reported a 2.5 percent fall in quarterly revenue, hurt by a strong dollar and declining sales of its Remicade arthritis treatment.
U.S. stock futures were higher this morning, following oil prices which were rising in early trading. The Dow dropped nearly 300 points Tuesday as U.S. crude tanked 5.5 percent.
Stocks enter the coming week on better footing, with economic data and earnings that could determine whether the economy is slowing.
With the earnings season in full swing, it's hard to keep track of who's reporting next. Luckily, CNBC's got you covered with this helpful look-ahead.
The rapid spread of the zika virus has spurred the hunt for a cure, but the financial incentive and likely length of time for a vaccine are unclear.
The "Fast Money" traders give their final trades of the day.
Karl-Ludwig Kley, chairman and CEO of Merck, is positive about the prospects for the health care and life sciences sector.
Regeneron CEO Len Schleifer says drug pricing needs to be balanced enough to support research and development.
Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.
Jim Cramer provides his take on caller favorite stocks, including this popular technology play that can't be touched.
China volatility. Oil selling off. Geopolitical tensions. The year did not get off to a good start for investors.
There's a case to be made for the Dogs of the Dow, even as stocks start 2016 down. They offer yields that can pay off a mortgage.